On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Right now, the FDA has approved the new drug to treat pain from an injury or surgery. Its manufacturer is also testing it for ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

Last month, the Food and Drug Administration approved that molecule, now called Journavx, as a treatment for the sharp, short-lived “acute” pain usually felt after an accident or a surgery.

Concerning your Journavx and OxyContin comment, 60 years ago our federal government for the first time was making its 1965 dimes and quarters with no silver content and mak ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...